Dendreon (DNDN) Elects John Johnson as Next CEO; Mitch Gold to Serve as Chairman
Tweet
Share
E-mailGet Alerts DNDN Hot Sheet
Join SI Premium – FREE
Dendreon Corporation (Nasdaq: DNDN) today announced that its Board of Directors has elected John H. Johnson to the position of president and chief executive officer (CEO), to succeed Mitchell H. Gold, MD, who has served as president and CEO for nearly a decade. Dr. Gold has been elected executive chairman and will serve in that role until June 30, 2012, at which point he will continue to serve as a director and Mr. Johnson will become chairman.
Johnson has been a member of Dendreon’s Board of Directors since August 2011 and brings to Dendreon nearly 30 years of experience in the life sciences industry, including serving as president, CEO, and director at Savient Pharmaceuticals, president of Eli Lilly’s Oncology Business Unit, CEO of ImClone System, and company group chairman of Johnson & Johnson’s Worldwide Biopharmaceuticals.
Johnson has been a member of Dendreon’s Board of Directors since August 2011 and brings to Dendreon nearly 30 years of experience in the life sciences industry, including serving as president, CEO, and director at Savient Pharmaceuticals, president of Eli Lilly’s Oncology Business Unit, CEO of ImClone System, and company group chairman of Johnson & Johnson’s Worldwide Biopharmaceuticals.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Katapult Holdings (KPLT) Announces Resignation of Chief Accounting Officer
- Rimini Street (RMNI) Appoints Steve Hershkowitz as Chief Revenue Officer
- Conmed (CNMD) Appoints Patrick Beyer as COO
Create E-mail Alert Related Categories
Management ChangesSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
